Bristol Myers (BMY) “Sell” Rating Reiterated at BMO Capital; The Target is Set to $49.0; Eaton Vance Senior Floating Rate Trust (EFR)’s Sentiment Is 1.26

November 15, 2017 - By Louis Casey

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.80’s average target is 2.53% above currents $61.25 stock price. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Citigroup on Tuesday, September 20. UBS maintained the stock with “Buy” rating in Friday, August 19 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Citigroup on Wednesday, October 18. Barclays Capital maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Tuesday, December 1. Barclays Capital has “Equal Weight” rating and $70 target. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Citigroup on Wednesday, October 25. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Buy” rating given on Friday, September 15 by Jefferies. The firm has “Market Perform” rating given on Monday, January 25 by BMO Capital Markets. As per Monday, July 17, the company rating was maintained by Deutsche Bank. The firm earned “Buy” rating on Friday, October 6 by UBS. The stock has “Hold” rating by Jefferies on Thursday, July 14.

Eaton Vance Senior Floating-Rate Trust is a diversified, closed-end management investment company. The company has market cap of $518.09 million. The Trust’s primary investment objective is to provide a high level of current income. It currently has negative earnings. The Trust may, as a secondary objective, also seek preservation of capital to the extent consistent with its primary objective.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has market cap of $100.25 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 24.1 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It is negative, as 78 investors sold Bristol-Myers Squibb Co shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Summit Asset Mngmt Limited Com holds 7,382 shares or 0.22% of its portfolio. Vaughan David Invs Il reported 13,215 shares. Lazard Asset Management Llc, a New York-based fund reported 729,447 shares. Roanoke Asset Mngmt Corporation Ny reported 66,385 shares. Thompson Rubinstein Inv Incorporated Or owns 9,600 shares for 0.2% of their portfolio. Germany-based Meag Munich Ergo Kapitalanlagegesellschaft Mbh has invested 0.28% in Bristol-Myers Squibb Co (NYSE:BMY). Shell Asset Mgmt Company stated it has 0.29% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Bokf Na reported 0.36% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Columbus Hill Capital Management L P owns 1.04M shares or 5.81% of their US portfolio. Marshwinds Advisory invested in 45,412 shares or 1.2% of the stock. 46,119 are owned by Lee Danner And Bass Inc. Loring Wolcott And Coolidge Fiduciary Advisors Llp Ma owns 35,015 shares for 0.04% of their portfolio. Port Solutions Limited Liability Company has invested 0% in Bristol-Myers Squibb Co (NYSE:BMY). The Ontario – Canada-based Td Asset Mgmt has invested 0.08% in Bristol-Myers Squibb Co (NYSE:BMY). Round Table Svcs Limited Liability Com holds 0.08% or 4,018 shares in its portfolio.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 25. They expect $0.67 EPS, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10 billion for 22.85 P/E if the $0.67 EPS becomes a reality. After $0.75 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.

The stock increased 0.44% or $0.27 during the last trading session, reaching $61.25. About shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 15, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Restructuring Capital Associates Lp holds 3.4% of its portfolio in Eaton Vance Senior Floating-Rate Trust for 264,843 shares. White Pine Capital Llc owns 162,473 shares or 0.96% of their US portfolio. Moreover, Robinson Capital Management Llc has 0.51% invested in the company for 77,882 shares. The Michigan-based Comerica Securities Inc has invested 0.32% in the stock. Aureus Asset Management Llc, a Massachusetts-based fund reported 62,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :